Clinical trial NCT05569811: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
Official title: A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Breast Cancer
Lead sponsor: SOLTI Breast Cancer Research Group
Sponsor class: OTHER
Collaborators: name: Daiichi Sankyo
First posted: 2022-10-06
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: VALENTINE is a parallel, non-comparative, three-arm, randomized 1:2:2 open-label, multicenter, exploratory study in women or men with primary operable HR+/HER2-negative breast cancer with ki67 ≥ 20% and/or high genomic risk (defined by gene signature) aiming at evaluating the clinical benefit and biological effects of HER3-DXd with/without letrozole as a neoadjuvant treatment regimen.

The primary aim is to evaluate the ability of each treatment strategy to achieve a pCR at surgery. This study is exploratory and no formal comparison between treatment arms is intended. The inclusion of a chemotherapy treatment arm serves as an internal response control instead of using historical data as comparators. In addition, the chemotherapy control arm is the standard of care appropriate treatment in these patients, to include this arm will ensure the recruitment of the target patient population (patients should have indication for neoadjuvant chemotherapy) and allowing comparison of secondary endpoint such as safety and/or HrQoL.


Eligibility criteria: Main inclusion criteria

1. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast untreated and recently diagnosed
2. ER-positive and/or PgR-positive and HER2-negative tumor
3. Ki67% ≥ 20% locally assessed and/or high genomic risk (defined by gene signature):
4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
5. Breast cancer eligible for primary surgery.
6. Availability of pre-treatment tumor tissue sample of FFPE tumor block from primary tumor for biomarker analysis.
7. Participants must be deemed eligible for neoadjuvant chemotherapy
8. Participants must be deemed eligible for surgery.
9. Adequate hematologic and end-organ function, defined by the following laboratory results
10. Baseline LVEF ≥ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan

Main exclusion criteria

1. Metastatic (Stage IV) breast cancer.
2. Bilateral invasive breast cancer.
3. Any treatment, local or systemic, including prior chemotherapy, ET, targeted therapy, and/or radiation therapy for the currently diagnosed BC prior to enrollment.
4. Patients in whom a primary tumor excisional biopsy was performed.
5. Prior treatment with a HER3 antibody, topoisomerase I inhibitor, with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., DS-8201) and with a govitecan derivative (e.g., IMMU-132).
6. Patient has active cardiac disease or a history of cardiac dysfunction.
7. Medical history of clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period.
8. Patients with a history of any malignancy are ineligible except specific cases
9. Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone fractures, psychiatric illness/social situations, geographical factors, substance abuse) or other factors which in the Investigator's opinion makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol
10. Concurrent, serious, uncontrolled infections or current known infection with HIV or active hepatitis B and/or hepatitis C.
11. History of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with ICF.
12. Known hypersensitivity to either the drug substance components (including an antibody, a drug-linker, or a topoisomerase I inhibitor) or inactive ingredients in the drug product or history of severe hypersensitivity reactions to other monoclonal antibodies.
13. History of exposure to cumulative anthracycline doses greater than follows: a. Adriamycin \> 100 mg/m2; Epirubicin \> 180 mg/m2; Mitoxantrone \> 40 mg/m2; Idarubicin \> 22.5 mg/m2. If another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of 100 mg/m2 of adriamycin.
14. Any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during screening.
15. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (i.e. rheumatoid arthritis, Sjögren's syndrome, sarcoidosis etc.), or prior pneumonectomy.
16. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, grade ≤1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the Investigator.
17. Non-eligible for taxanes therapy. Previous sensory neuropathy \> grade 1, according to NCI-CTCAE criteria, due to any reason.
18. Is receiving chronic systemic corticosteroids dosed at \>10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Subjects who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
19. Evidence of any leptomeningeal disease.
20. Has clinically significant corneal disease.
21. Female subject who is pregnant or breastfeeding or intends to become pregnant during the study.
22. Subjects who are currently receiving chloroquine or hydroxychloroquine. A washout period of \> 14 days is required prior to randomization or Cycle 1 Day 1

Primary outcomes:
measure: Rate of pCRBL (ypT0/is ypN0) at surgery
timeFrame: before treatment and surgery
Secondary outcomes:
measure: Rate of Residual cancer burden (RCB) category status (0, I, II, III)
timeFrame: before treatment and surgery
measure: pCRB (pathological complete response in the breast)
timeFrame: before treatment and surgery
measure: Tumor overall objective response rate (ORR)
timeFrame: before treatment and pre-surgery
measure: iDFS rate
timeFrame: 3 years follow-up and 5 years follow-up
measure: CelTIL score changes
timeFrame: from baseline to C2D1
measure: HER3 receptor expression and ERBB3 mRNA expression level
timeFrame: from baseline to C2D1
measure: Proliferation
timeFrame: from baseline to C2D1
measure: Quality of Life assessed by EORTC-BR45 changes
timeFrame: from baseline until 30 days after the surgery visit
measure: Quality of Life assessed by EORTC QLQ-C30 changes
timeFrame: from baseline until 30 days after the surgery visit
measure: Number of Participants with Adverse events (safety)
timeFrame: from randomization/enrollment to end of safety follow up assessed up to approximately 30 days after the surgery visit
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: ICO Badalona
state: Barcelona
city: Tenerife
country: Spain
facility: Hospital Universitario de Canarias
state: Islas Canarias
city: A Coruña
country: Spain
facility: Complejo Hospitalario Universitario A Coruña (CHUAC)
state: La Coruña
city: Fuenlabrada
country: Spain
facility: Hospital Universitario de Fuenlabrada
state: Madrid
city: Móstoles
country: Spain
facility: Hospital Universitario Rey Juan Carlos
state: Madrid
city: Badajoz
country: Spain
facility: Hospital Universitario de Badajoz
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Barcelona
country: Spain
facility: Hospital General de Catalunya
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d' Hebrón
city: Bilbao
country: Spain
facility: Hospital de Basurto
city: Cáceres
country: Spain
facility: Complejo Hospitalario San Pedro de Alcántara
city: Córdoba
country: Spain
facility: Hospital Universitario Reina Sofia
city: Granada
country: Spain
facility: Hospital Universitario Virgen de las Nieves
city: Lleida
country: Spain
facility: H.Univ. Arnau de Vilanova de Lleida
city: Madrid
country: Spain
facility: Hospital Universitario Puerta de Hierro de Majadahonda
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Manresa
country: Spain
facility: HAU de Manresa
city: Murcia
country: Spain
facility: Hospital Universitario Virgen de la Arrixaca
city: Palma De Mallorca
country: Spain
facility: Hospital Son Espases
city: Reus
country: Spain
facility: Hospital Sant Joan de Reus
city: Sabadell
country: Spain
facility: HU Parc Tauli
city: Santiago De Compostela
country: Spain
facility: Comp. Hosp.Univ. Santiago (Chus)
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio
city: Valencia
country: Spain
facility: H La Fe
city: Valencia
country: Spain
facility: Hospital Clínico de Valencia
Study officials:
References: